Commentary · 1 Feb 2023
Byline
J. Michiels
Articles whose byline reads J. Michiels, printed most often as Jan Jacques Michiels, J J Michiels, Michiels JJ, Jan Michiels and Janneke Maria Michiels. Different authors can share a byline.
- Articles
- 59
- Latest year
- 2023
Articles
Newest first. Showing 1–25 of 59 articles.
Editorial · 16 Dec 2019
Announcement of 17th International Conference on Cancer Science and Radiation Oncology
Conference abstract · 2019
TRANSLATION OF PVSG/WHO INTO THE CLINICAL, LABORATORY, MOLECULAR AND PATHOLOGICAL (2018 CLMP) DEFINED MYELOPROLIFERATIVE NEOPLASMS CAUSED BY JAK2V617F JAK2EXON12, CALR, MPL AND TPO DRIVER MUTATIONS ARE DISTINCT BLOOD AND COAGULATION DISORDERS: PROGNOSTIC AND THERAPEUTIC IMPLICATIONS TOWARDS 2020 AND BEYOND
Conference abstract · 2019
The PVSG/WHO versus the clinical, laboratory, molecular and pathological (2018 CLMP) defined myeloproliferative neoplasms caused by JAK2V617F JAK2EXON12, CALR, MPL and TPO driver mutations are distinct blood & coagulation disorders: Prognostic and therapeutic implications towards 2020 and beyond
Conference abstract · 2019
Change of the 2008/16 WHO into 2018 clinical, laboratory, molecular and pathobiological (WHO-CLMP) criteria for diagnosis of the meloproliferative neoplasms JAK2V617F trilinear polycythemia vera (PV), JAK2 exon 12 PV and JAK2V617F, CALR or MPL515 mutated thrombocythemias and secondary myelofibrosis
Conference abstract · 24 Sep 2018
Common etiologic pathways in platelet-mediated aspirin responsive erythromelalgia and arteriolar platelet thrombophilia in JAK2, MPL or CALR mutated thrombocythemia and incurable Nav1.7 neuropathic erythrothermalgia due
Conference abstract · 24 Sep 2018
Improved criteria for clinical, laboratory, molecular and pathologic (2018 clmp) diagnosis and staging of Prefibrotic JAK2, CALR And MPL mutated Myeloproliferative Neoplasms
Conference abstract · 21 Aug 2018
Evaluation of classical and novel von Willebrand factor assays in von Willebrand disease patients
Conference abstract · 21 Aug 2018
Clinical, Laboratory, Molecular and Pathobiological (CLMP) criteria for diagnosis of the Myeloproliferative Neoplasms JAK2V617F trilinear polycythemia vera (PV), JAK2 exon 12 PV and JAK2V617F, CALR or MPL mutated thrombocythemias and myelofibrosis
Conference abstract · 2018
Novel insights in the diagnosis and classification of autosomal recessive and dominant von Willebrand diseases anno 2018
Conference abstract · 2018
Molecular and laboratory characteristics of recessive von Willebrand Disease 2N anno 2018
Conference abstract · 2018
Evaluation of classical and novel von Willebrand Factor assays in ECLM defined von Willebrand disease patients
Conference abstract · 2018
The 2001-2016 World Health Organization vs. European clinical, molecular and pathological and the 2008-2018 clinical, laboratories, molecular and pathological (CLMP): Euro-Asian classification of JAK2, CALR and MPL mutated myeloproliferative neoplasms
Research article · 2018
Determination of Two Rapid Von Willebrand Factor (VWF) Activity assays VWF: Gpibm and VWF: Gpibr in Well Defined Von Willebrand Disease Patients Using a Complete Set of Classical and Sensitive VWF Assays
Case report · 2018
Bone Marrow Histology Characteristics in MPL515 Mutated Thrombocythemia with Various Degrees of Myelofibrosis: A Cross Sectional Follow-up Study in Eight Cases
Conference abstract · 2018
Novel criteria for clinical, laboratory, molecular and pathologic (2018 CLMP) diagnosis and staging of prefibrotic JAK2, CALR and MPL mutated myeloproliferative neoplasms
Research article · 2018
Novel Evidence-Based Diagnosis, Classification and Management of Lower Extremity Deep Vein Thrombosis (DVT), Prevention of DVT Recurrence and the Post-Thrombotic Syndrome: Personal Experiences and Critical Appraisal of the Literature 1998-2018
Conference abstract · 5 Oct 2017
Translation of WHO into improved clinical, laboratory, molecular and pathological (CLMP) criteria for the diagnoses of JAK2 trilinear myeloproliferative neoplasm, MPL thrombocythemia and CALR thrombocythemia and myelofib
Conference abstract · 5 Oct 2017
Extension of 2016 World Health Organization (WHO) classification into a new set of clinical, laboratory, molecular, and pathological criteria for the diagnosis of myeloproliferative neoplasms: from dameshek to vainchenke
Conference abstract · 5 Oct 2017
Sticky platelet syndrome and MPN disease burden in JAK2 thrombocythemia and polycythemia vera, and in JAK2, mpl and calr thrombocythemias: Implications for novel non-leukemogenic treatment options in prefibrotic myelopro
Conference abstract · 28 Aug 2017
Clinical, Laboratory, Molecular and Pathological (CLMP) Euro-Asian classification and treatment options of prefibrotic JAK2, CALR and MPL mutated myeloproliferative Neoplasm
Conference abstract · 26 Jun 2017
Aspirin responsive erythromelalgia in JAK2-thrombocythemia and incurable inherited erythrothermalgia in neuropathic Nav1.7 sodium channelopathy: From Mitchell 1878 to Michiels 2017
Research article · 2017
Acquired Von Willebrand Syndrome (AVWS) Type 2A as the Presenting Feature of JAK2 Wild type Thrombocythemia in a Child: Effectiveness of Platelet Reduction by Anagrelide
Research article · 2017
Myelofibrosis is a Secondary Event in JAK2 Trilinear Myeloproliferative Neoplasm (MPN) and in CALR and MPL Thrombocythemia: Implications for Novel Treatment Options of Prefibrotic MPN
Review article · 2017

